{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:38Z","timestamp":1748971778994,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jhep.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T05:38:49Z","timestamp":1546753129000},"page":"348-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-1702","authenticated-orcid":false,"given":"James H.","family":"Tabibian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.12.006_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.12.006_b0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2012.10.011","article-title":"The dynamic biliary epithelia: molecules, pathways, and disease","volume":"58","author":"O'Hara","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.12.006_b0015","series-title":"Blumgart\u2019s surgery of the liver, biliary tract and pancreas","article-title":"Primary sclerosing cholangitis","author":"Tabibian","year":"2017"},{"key":"10.1016\/j.jhep.2018.12.006_b0020","article-title":"Complications, symptoms, quality of life and pregnancy in cholestatic liver disease","author":"Zakharia","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.12.006_b0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.6000\/1927-7229.2012.01.01.7","article-title":"Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis","volume":"1","author":"Tabibian","year":"2012","journal-title":"J Anal Oncol"},{"key":"10.1016\/j.jhep.2018.12.006_b0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2017.12.002","article-title":"Primary sclerosing cholangitis: a review and update","volume":"1","author":"Tabibian","year":"2017","journal-title":"Liver Res"},{"key":"10.1016\/j.jhep.2018.12.006_b0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOG.0000000000000333","article-title":"The evolution of natural history of primary sclerosing cholangitis","volume":"33","author":"Takakura","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2018.12.006_b0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.27180","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)","volume":"60","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.12.006_b0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, a FGF19 analogue, in primary sclerosing cholangitis: a multicentre, randomized, double-blind, placebo-controlled phase 2 trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.12.006_b0050","first-page":"815433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2018.12.006_b0055","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.12.006_b0060","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","author":"Vesterhus","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.12.006_b0065","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.12.006_b0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.12.006_b0075","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1665-2681(19)30869-5","article-title":"Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis","volume":"13","author":"Tabibian","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2018.12.006_b0080","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2018.12.006_b0085","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.12.006_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12072-016-9769-7","article-title":"Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge","volume":"11","author":"Zweers","year":"2017","journal-title":"Hepatol Int"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818326230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818326230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T20:26:02Z","timestamp":1662755162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818326230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0168827818326230"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.12.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.10.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}